Skip to main content
SpringerLink
Log in

Coronary Heart Disease in HIV-Infected Patients: Epidemiology

  • Chapter
Book cover Cardiovascular Disease in AIDS

  • 461 Accesses

Abstract

Cardiovascular disease continues to be the leading cause of death among the general population of industrialized countries. It is also the main reason for hospitalization. But what about HIV-infected subjects? With the advent of combination antiretroviral therapy (cART) for HIV infection, including protease inhibitors (PIs), in April 1996 in France, the morbidity of AIDS-defining illnesses has been reduced and HIV-infected patients are living longer [1, 2]. Thus, the spectrum of diseases related to HIV is shifting from opportunistic diseases towards long-term complications such as cancers, coinfection with other viruses such as hepatitis C virus, and the metabolic effects of cART. Some of these disorders are potential risk factors for cardiovascular diseases and so could lead to cardiovascular over-mortality and over-morbidity. Cardiovascular diseases currently account for 7% of deaths among HIV-infected subjects in France, for 14% of non-HIV-related deaths [3], and about 16% of deaths among subjects with a good immunovirologic response to cART [4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Palella FJ Jr, Delaney KM, Moorman AC et al (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators. N Engl J Med 338:853–860

    Article  PubMed  Google Scholar 

  2. The CASCADE Collaboration (2000) Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet 355:1158–1159

    Article  Google Scholar 

  3. Lewden C, Salmon D, Morlat P et al (2004) Causes of death among HIV-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 34:121–130

    Article  PubMed  Google Scholar 

  4. May T, Lewden C, Bonnet F et al (2004) Causes et caractéristiques des décès des patients infectés par le VIH-1, en succes immuno-virologique sous traitement antirétroviral. Presse Med 33:1487–1492

    Article  CAS  PubMed  Google Scholar 

  5. Delfraissy JF (2006) Prise en charge thérapeutique des personnes infectées par le HIV. Mise á jour 2006. Recommandations du groupe d’experts sous la direction du Pr P Yéni. Flammarion Médecine-Sciences, Paris

    Google Scholar 

  6. Hammer SM, Saag MS, Schechter M et al (2006) Treatment for adult HIV infection: 2006 recommendations of the International AIDS SocietyUSA Panel. JAMA 296:827–843

    Article  CAS  PubMed  Google Scholar 

  7. Grunfeld C, Pang M, Doerrler W et al (1992) Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 74:1045–1052

    Article  CAS  PubMed  Google Scholar 

  8. Feingold KR, Krauss RM, Pang M et al (1993) The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab 76:559–565

    Article  Google Scholar 

  9. Carr A, Samaras K, Burton S et al (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitor. AIDS 12:F51–F58

    Article  CAS  PubMed  Google Scholar 

  10. Carr A, Samaras K, Thorisdottir A et al (1999) Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353:2093–2099

    Article  CAS  PubMed  Google Scholar 

  11. Safrin S, Grunfeld C (1999) Fat distribution and metabolic changes in patients with HIV infection. AIDS 13:2493–2505

    Article  CAS  PubMed  Google Scholar 

  12. Hadigan C, Meigs JB, Corcoran C et al (2001) Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 32:130–139

    Article  CAS  PubMed  Google Scholar 

  13. Tabib A, Greenland T, Mercier I et al (1992) Coronary lesions in young HIV-positive subjects at necropsy. Lancet 340:730

    Article  CAS  PubMed  Google Scholar 

  14. Paton P, Tabib A, Loire R, Tete R (1993) Coronary artery lesions and human immunodeficiency virus infection. Res Virol 144:225–231

    Article  CAS  PubMed  Google Scholar 

  15. Henry K, Melroe H, Huebsch J et al (1998) Severe premature coronary artery disease with protease inhibitors. Lancet 351:1328

    Article  CAS  PubMed  Google Scholar 

  16. Behrens G, Schmidt H, Meyer D et al (1998) Vascular complications associated with use of HIV protease inhibitors. Lancet 351:1958

    Article  CAS  PubMed  Google Scholar 

  17. Gallet B, Pulik M, Genet P et al (1998) Vascular complications associated with use of HIV protease inhibitors. Lancet 351:1958–1959

    Article  CAS  PubMed  Google Scholar 

  18. Laurence J (1998) Vascular complications associated with use of HIV protease inhibitors. Lancet 351:1960

    Article  CAS  PubMed  Google Scholar 

  19. Flynn TE, Bricker LA (1999) Myocardial infarction in HIV-infected men receiving protease inhibitors. (letter) Ann Intern Med 131:548

    CAS  PubMed  Google Scholar 

  20. Friedl AC, Attenhofer Jost CH, Schalcher C et al (2000) Acceleration of confirmed coronary artery disease among HIV-infected patients on potent antiretroviral therapy. AIDS 14:2790–2792

    Article  CAS  PubMed  Google Scholar 

  21. Karmochkine M, Raguin G (1998) Severe coronary artery disease in a young HIV-infected man with no cardiovascular risk factors who was treated with indinavir. AIDS 12:2499

    CAS  PubMed  Google Scholar 

  22. Eriksson U, Opravil M, Amann FW, Schaffner A (1998) Is treatment with ritonavir a risk factor for myocardial infarction in HIV-infected patients? AIDS 12:2079–2080

    Article  CAS  PubMed  Google Scholar 

  23. Koppel K, Bratt G, Rajs J (1999) Sudden cardiac death in a patient on 2 years of highly active antiretroviral treatment: a case report. AIDS 13:1993–1994

    Article  CAS  PubMed  Google Scholar 

  24. Vittecoq D, Escaut J, Monsuez JJ (1998) Vascular complications associated with use of HIV protease inhibitors. Lancet 351:1959

    Article  CAS  PubMed  Google Scholar 

  25. Passalaris JD, Sepkowitz KA, Glesby MJ (2000) Coronary artery disease and human immunodeficiency virus infection. Clin Infect Dis 31:787–797

    Article  CAS  PubMed  Google Scholar 

  26. Jütte A, Schwenk A, Franzen D et al (1999) Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment? (letter) AIDS 13:1796–1797

    Article  PubMed  Google Scholar 

  27. Rickerts V, Brodt HR, Staszewski S, Stille W (2000) Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: The Frankfurt HIV-cohort study. Eur J Med Res 5:329–333

    CAS  PubMed  Google Scholar 

  28. Holmberg SD, Moorman AC, Williamson JM et al (2002) Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 360:1747–1748

    Article  CAS  PubMed  Google Scholar 

  29. Friis-Møller N, Sabin CA, Weber R et al (2003) Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349:1993–2003

    Article  PubMed  Google Scholar 

  30. Moore RD, Keruly JC, Lucas G (2003) Increasing incidence of cardiovascular disease in HIV-infected persons in care. 10th conference on retroviruses and opportunistic infections, Boston, USA, 10-14 February 2003. Abstract no. 132

    Google Scholar 

  31. Mary-Krause M, Cotte L, Simon A et al (2003) Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIVinfected men. AIDS 17:2479–2486

    Article  PubMed  Google Scholar 

  32. DAD Study Group, Friis-Møller N, Reiss P, Sabin CA et al (2007) Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 356:1723–1735

    Article  PubMed  Google Scholar 

  33. David MH, Hornung R, Fichtenbaum CJ (2002) Ischemic cardiovascular disease in persons with human immunodeficiency virus infection. Clin Infect Dis 34:98–102

    Article  PubMed  Google Scholar 

  34. Klein D, Hurley LB, Quesenberry CP, Sidney S (2002) Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 30:471–477

    CAS  PubMed  Google Scholar 

  35. Klein D, Hurley M (2003) Hospitalizations for coronary heart disease and myocardial infarction among men with HIV-1 infection: additional follow-up. 10th conference on retroviruses and opportunistic infections, Boston, USA, 10-14 February 2003, Abstract no. 747

    Google Scholar 

  36. Bozzette SA, Ake CF, Tam HK et al (2003) Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 348:702–710

    Article  CAS  PubMed  Google Scholar 

  37. Bozette SA, Ake CF, Tam HK et al (2008) Longterm survival and serious cardiovascular events in HIV-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 47:338–341

    Article  Google Scholar 

  38. D’Arminio Monforte A, Sabin CA, Phillips AN et al (2004) Cardioand cerebrovascular events in HIV-infected persons. AIDS 18:1811–1817

    Article  Google Scholar 

  39. Sabin CA, Worm SW, Weber R et al (2008) Recent use of Abacavir and didanosine, but not of Thymidine Analogues, is associated with risk of myocardial infarction. 15th Conference on Retroviruses and Opportunistic Infections, Boston, USA, February 3-6, 2008. Abstract n957c.

    Google Scholar 

  40. DAD Study Group, Sabin CA, Worm SW, Weber R et al (2008) Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371:1417–1426

    Article  CAS  PubMed  Google Scholar 

  41. Anonymous (2000) Les registres français de cardiopathies ischémiques 1997-1998. Fédération Française de cardiologie, Paris

    Google Scholar 

  42. Depairon M, Chessex S, Sudre P et al (2001) Premature atherosclerosis in HIV-infected individuals: focus on protease inhibitor therapy. AIDS 15:329–334

    Article  CAS  PubMed  Google Scholar 

  43. Savès M, Chêne G, Ducimetière P et al (2003) Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 37:292–298

    Article  PubMed  Google Scholar 

  44. Currier JS, Taylor A, Boyd F et al (2003) Coronary heart disease in HIV-infected individuals. J Acquir Immune Deficit Syndr 35:506–512

    Google Scholar 

  45. Smith C, Levy I, Sabin C et al (2004) Cardiovascular disease risk factors and antiretroviral therapy in HIV-positive UK population. HIV Med 5:88–92

    Article  CAS  PubMed  Google Scholar 

  46. Anonymous (1977) Manuel de la classification statistique internationale des maladies, traumatismes et causes de décès, Révision 1975. Organisation Mondiale de la Santé, Geneva

    Google Scholar 

  47. Klein D, Hurley L, Silverberg M et al (2007) Surveillance data for myocardial infarction hospitalizations among HIV+ and HIVNorthern California. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, USA, 25-28 February 2007, Abstract no. 807

    Google Scholar 

  48. El-Sadr WM, Lundgren JD, Neaton JD et al; Strategies for Management of Antiretroviral Therapy (SMART) Study Group (2006) CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355:2283–2296

    Article  CAS  PubMed  Google Scholar 

  49. Barbaro G, Di Lorenzo G, Soldini M et al Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS (GISCA) (1999) Intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus-associated cardiomyopathy. Circulation 100:933–939

    CAS  PubMed  Google Scholar 

  50. Matetzky S, Domingo M, Kar S et al (2003) Acute myocardial infarction in human immunodeficiency virus-infected patients. Arch Intern Med 163:457–460

    Article  PubMed  Google Scholar 

  51. Hsue PY, Giri K, Erickson S et al (2004) Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. Circulation 109:316–319

    Article  PubMed  Google Scholar 

  52. Law M, Friis-Møller N, Weber R et al (2003) Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Med 4:1–10

    Article  CAS  PubMed  Google Scholar 

  53. Dube MP, Stein JH, Aberg JA et al (2003) Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 37:613–627

    Article  PubMed  Google Scholar 

  54. Department of Health and Human Services (2004) Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. AIDSinfo, Rockville, MD, USA. http://www. AIDSinfo.nih.gov/guidelines. Cited 23 March 2004

    Google Scholar 

  55. Fellay J, Boubaker K, Lederberger B et al (2001) Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV cohort Study. Lancet 358:1322–1327

    Article  CAS  PubMed  Google Scholar 

  56. Friis-Møller N, Weber R, Reiss P et al (2003) Cardiovascular disease risk factors in HIV patientsassociation with antiretroviral therapy. Results from the DAD study. AIDS 17:1179–1193

    Google Scholar 

  57. Fontas E, van Leth F, Sabin CA et al (2004) Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 189:1056–1074

    Article  CAS  PubMed  Google Scholar 

  58. Haubrich RH, Riddler S, DiRienzo G et al (2007) Metabolic Outcomes of ACTG 5142: A Prospective, Randomized, Phase III Trial of NRTI-, PI-, and NNRTI-sparing Regimens for Initial Treatment of HIV-1 Infection. 14th conference on retroviruses and opportunistic infections, Los Angeles, USA, February 25-28, 2007. Abstract no. 38

    Google Scholar 

  59. van der Valk M, Friis-Moller N, Sabin C et al (2006) Effects of different interventions to improve ART-associated dyslipidemia. 8th international congress on drug therapy in HIV infection, Glasgow, UK, November 12-16, 2006. Abstract no. PL12.2

    Google Scholar 

  60. Falusi OM, Aberg JA (2001) HIV and cardiovascular risk factors. AIDS Reader 11:263–268

    CAS  PubMed  Google Scholar 

  61. Chiuve SE, McCullough ML, Sacks FM, Rimm EB (2006) Healthy lifestyle factors in the primary prevention of coronary heart disease among men: benefits among users and nonusers of lipid-lowering and antihypertensive medications. Circulation 114:160–167

    Article  PubMed  Google Scholar 

  62. Glass TR, Ungsedhapand C, Wolbers M et al (2006) Prevalence and risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV cohort study. HIV Med 7:404–410

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. INSERM U720, Epidémiologie Clinique et Traitement de l’Infection à VIH, Université Pierre et Marie Curie, Paris, France

    M. Mary-Krause & D. Costagliola

Authors
  1. M. Mary-Krause
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Costagliola
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medical Pathophysiology, “Sapienza” University of Rome, Rome, Italy

    Giuseppe Barbaro

  2. Department of Cardiology Saint Antoine University Hospital, Assistance Publique - Hôpitaux de Paris and Université Pierre et Marie Curie Paris, France

    Franck Boccara

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag Italia

About this chapter

Cite this chapter

Mary-Krause, M., Costagliola, D. (2009). Coronary Heart Disease in HIV-Infected Patients: Epidemiology. In: Barbaro, G., Boccara, F. (eds) Cardiovascular Disease in AIDS. Springer, Milano. https://doi.org/10.1007/978-88-470-0761-1_8

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-0761-1_8

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-0760-4

  • Online ISBN: 978-88-470-0761-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation